64
Participants
Start Date
September 3, 2021
Primary Completion Date
August 24, 2024
Study Completion Date
August 24, 2025
S-1, leucovorin, oxaliplatin and gemcitabine
"Gemcitabine 800 mg/m2 on day 1, oxaliplatin 85 mg/m2 on day 1, S-1 orally 80-120 mg/day \[depending on patient's body surface area (BSA)\] on day 1 to 7 and leucovorin 30mg BID day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~* BSA \< 1.25 m2: 80 mg/day~* 1.25 m2 ≤ BSA \< 1.5 m2: 100 mg/day~* BSA ≥ 1.5 m2: 120 mg/day"
RECRUITING
Kaohsiung Medical University Hospital, Kaohsiung City
RECRUITING
National Cheng-Kung University Hospital, Tainan City
RECRUITING
National Institute of Cancer Research, Tainan City
National Health Research Institutes, Taiwan
OTHER